
Arthur E Frankel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1616901/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors. EClinicalMedicine, 2021, 34, 100797.	3.2	115
2	HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2020, 26, 793-803.	3.2	117
3	Cancer Immune Checkpoint Inhibitor Therapy and the Gut Microbiota. Integrative Cancer Therapies, 2019, 18, 153473541984637.	0.8	48
4	Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis. British Journal of Cancer, 2018, 119, 928-936.	2.9	66
5	A STING-activating nanovaccine for cancer immunotherapy. Nature Nanotechnology, 2017, 12, 648-654.	15.6	649
6	Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood, 2017, 130, 722-731.	0.6	1,173
7	Academic Cancer Center Phase I Program Development. Oncologist, 2017, 22, 369-374.	1.9	0
8	Digoxin Plus Trametinib Therapy Achieves Disease Control in BRAF Wild-Type Metastatic Melanoma Patients. Neoplasia, 2017, 19, 255-260.	2.3	35
9	Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients. Neoplasia, 2017, 19, 848-855.	2.3	475
10	Blastic plasmacytoid dendritic cell neoplasm with t(11;19)(q23;p13.3); <i><scp>KMT</scp>2A</i> (<i><scp>MLL</scp></i>) rearranged: a diagnostic challenge. British Journal of Haematology, 2017, 176, 8-8.	1.2	4
11	Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma. Nature Communications, 2016, 7, 12336.	5.8	43
12	Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2–mutated blastic plasmacytoid dendritic cell neoplasm. Human Pathology, 2015, 46, 322-326.	1.1	8
13	Human recombinant arginase enzyme reduces plasma arginine in mouse models of arginase deficiency. Human Molecular Genetics, 2015, 24, 6417-6427.	1.4	40
14	Phospho-MEK1/2 and uPAR Expression Determine Sensitivity of AML Blasts to a Urokinase-Activated Anthrax Lethal Toxin (PrAgU2/LF). Translational Oncology, 2015, 8, 347-357.	1.7	10
15	Resimmune, an anti-CD3Â recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma. Haematologica, 2015, 100, 794-800.	1.7	46
16	Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial. Blood, 2015, 126, 323-323.	0.6	57
17	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Large Single-Center Experience: Analysis of Clinical and Molecular Characteristics and Patient Outcomes. Blood, 2015, 126, 3746-3746.	0.6	11
18	Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood, 2014, 124, 385-392.	0.6	195

#	Article	IF	CITATIONS
19	An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood, 2013, 122, 2682-2682.	0.6	7
20	An Update On The Clinical Activity Of Resimmune, a Targeted Therapy Directed To CD3 Receptor, In Patients With Cutaneous T Cell LymphomasCTCL. Blood, 2013, 122, 4381-4381.	0.6	4